Actively Recruiting

Phase 1
Age: 60Years - 85Years
All Genders
Healthy Volunteers
NCT06843317

Safety and Immunogenicity Study of Revaccination With SCB-1019T in Healthy Adults

Led by Clover Biopharmaceuticals USA, LLC · Updated on 2025-05-14

160

Participants Needed

5

Research Sites

62 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

CLO-SCB-1019-002 is the first study of SCB-1019T vaccine for revaccination in older adults who were previously vaccinated with AREXVY. The safety, tolerability and immunogenicity of SCB-1019T are assessed.

CONDITIONS

Official Title

Safety and Immunogenicity Study of Revaccination With SCB-1019T in Healthy Adults

Who Can Participate

Age: 60Years - 85Years
All Genders
Healthy Volunteers

Eligibility Criteria

Eligible

You may qualify if you...

  • Male and female participants 60-85 years of age at the screening visit who received AREXVY before
  • Willing and able to comply with study requirements including visits, vaccination, lab tests, and procedures
  • Willing and able to give informed consent prior to screening
  • Healthy participants or those with stable medical conditions not requiring recent therapy changes or hospitalization
Not Eligible

You will not qualify if you...

  • Acute disease or fever (≥38°C) at time of vaccination; minor illness without fever may be allowed
  • Recurrent or uncontrolled neurological disorders or seizures
  • Serious or unstable chronic illnesses
  • History of dementia or medical conditions impairing cognition moderately or severely
  • History of severe adverse reaction to vaccines or severe allergy to vaccine components

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 5 locations

1

AMR Phoenix

Phoenix, Arizona, United States, 85282

Actively Recruiting

2

AMR Fort Myers

Fort Myers, Florida, United States, 33912

Actively Recruiting

3

AMR Lexington

Lexington, Kentucky, United States, 40509

Actively Recruiting

4

AMR Kansas City

Kansas City, Missouri, United States, 64114

Actively Recruiting

5

Knoxville

Knoxville, Tennessee, United States, 37909

Actively Recruiting

Loading map...

Research Team

X

Xuesong Pei, MD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

QUADRUPLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

PREVENTION

Number of Arms

4

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Safety and Immunogenicity Study of Revaccination With SCB-1019T in Healthy Adults | DecenTrialz